Exclusive Summary

• - Patent barriers are cleared globally (EU ~2013, US entry from 2017, JP 2014), making 100 mg a fast-to-launch, mature strength across markets.
• - Massive and growing ED population (~322M men by 2025) sustains stable demand; 100 mg is commonly used after titration in first-line PDE5i therapy.
• - PDE5 inhibitors are guideline-endorsed first-line for ED; WHO EML lists sildenafil for PAH (supporting safety/access), though not for ED.
• - Competition is intense (US >30 ANDAs, many EU MA holders, 100+ brands in India); differentiation hinges on reliable supply, flexible packs, and multi-channel coverage.
• - API meets BP/USP/EP, enabling cross-region spec alignment; generics typically offer 70–95% price cuts vs originator, delivering strong value.

Asset Materials

Contact Us for Full Materials